MHRA approves second of two GMP manufacturing suites for COVID-19 vaccine candidate
The two suites, established with VMIC equipment and operated by Oxford Biomedica, will be operating at 1000-L scale.
The Vaccines Manufacturing and Innovation Centre (VMIC) has announced today that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has now approved the second of two GMP manufacturing suites that house VMIC’s specialist vaccines manufacturing equipment, resulting in two fully equipped, approved manufacturing suites to make a leading COVID-19 vaccine candidate.
As part of the national response to develop vaccine for COVID-19, the two suites established with VMIC equipment will be operating at 1000-L scale and will be dedicated to the manufacture of a leading COVID-19 viral vector vaccine candidate.
The suites, operated by Oxford Biomedica, are located in their commercial manufacturing centre, Oxbox, in Oxford, UK and are expected to be fully operational in October.
Supported by government funding through UK Research and Innovation, the collaboration between VMIC and Oxford Biomedica signed in June 2020 enabled the UK to establish a rapid deployment centre or ‘Virtual VMIC’ while the permanent VMIC facility was being built. The aim being to rapidly build capability in the UK to manufacture a vaccine for COVID-19 rather than wait until VMIC’s permanent facility opens in 2021.
Dr Matthew Duchars, Chief Executive, VMIC, said the suites will have the ability to make "tens of millions of doses" of the current leading vaccine candidate.
The permanent VMIC facility, due to open in 2021, will be located at the Harwell Science and Innovation Campus in Oxfordshire, UK.
The facility will house specialist equipment drawing on both innovative and traditional technologies. It is envisaged that much of the work at the new facility will be collaborative ventures with organisations ranging from small and medium sized businesses, through to large multinationals and non-governmental organisations such as Wellcome and CEPI, thereby underpinning the activity and strength of the UK in the vaccine area.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance